Adial Pharmaceuticals
ADIL
13 hedge funds and large institutions have $296K invested in Adial Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
53% more capital invested
Capital invested by funds: $194K → $296K (+$102K)
18% more funds holding
Funds holding: 11 → 13 (+2)
0.06% more ownership
Funds ownership: 0.12% → 0.18% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$49.6K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$28.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$22.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$17.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$27.1K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.44K |
| 3 |
Morgan Stanley
New York
|
-$312 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $62.5K | +$17K | +655 | +36% |
|
|
2
Citadel Advisors
Miami,
Florida
| $55.1K | +$22.1K | +849 | +64% |
|
|
MCM
3
Manchester Capital Management
Manchester,
Vermont
| $48.6K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $48.1K | +$49.6K | +1,905 | New |
|
5
BlackRock
New York
| $28K | – | – | – |
|
|
6
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $27K | +$28.1K | +1,080 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $21.2K | +$17.3K | +665 | +378% |
|
|
1IA
8
1620 Investment Advisors
Plymouth,
Massachusetts
| $3.64K | – | – | – |
|
|
SS
9
SBI Securities
Tokyo,
Japan
| $946 | +$963 | +37 | New |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $644 | -$3.44K | -132 | -84% |
|
11
Wells Fargo
San Francisco,
California
| $162 | +$156 | +6 | New |
|
12
Bank of America
Charlotte,
North Carolina
| $53 | – | – | – |
|
|
AWM
13
Abound Wealth Management
Franklin,
Tennessee
| $28 | – | – | – |
|
|
14
Morgan Stanley
New York
| $9 | -$312 | -12 | Closed |
|
|
TSS
15
Two Sigma Securities
New York
| – | -$27.1K | -1,085 | Closed |
|
ADIL Hedge Fund Activity: Q4 2024 in Review
13 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q4 2024, worth a combined $296K — up 53% from $194K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ADIL positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $49.6K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $27.1K sold.
- 13 institutional investors held Adial Pharmaceuticals (ADIL) as of Q4 2024, up from 11 in Q3 2024.
- Funds reported $296K of Adial Pharmaceuticals stock for Q4 2024, up 53% quarter-over-quarter.
- 4 funds opened new Adial Pharmaceuticals positions in Q4 2024 and 2 closed out, a net change of +2 holders.
- The largest Adial Pharmaceuticals buyer in Q4 2024 was Renaissance Technologies, an estimated $49.6K added.
- The largest Adial Pharmaceuticals seller in Q4 2024 was Two Sigma Securities, an estimated $27.1K sold.
Based on aggregated 13F filings for Q4 2024.